The fourth in this week’s series, building on earlier pieces, brings the focus squarely onto the PBS, arguing that spending on medicines has not truly slowed, but has shifted decisively from government to consumers, reshaping how the PBS functions, what it can fund, and the policy choices now confronting decision-makers.
The PBS paradox - a rising medicine spend, but a shrinking investment capacity
January 20, 2026 Latest NewsBioPharmaNews of the Day
Latest Video
New Stories
-
LifeSciences Australia honours outstanding professionals at MTP Sector Awards 2026
June 12, 2026 - - Latest News -
'The changes could cause irreversible damage to our vibrant and world-leading biotech, medtech and health tech sector'
June 12, 2026 - - Australian Biotech -
The opportunity to change the conversation, the negotiating dynamic, and take some control
June 12, 2026 - - Latest News -
State and Territory ministers warn against centralising NDIS power
June 12, 2026 - - Latest News -
ARCS evolves into LifeSciences Australia as part of wider strategic change
June 11, 2026 - - Latest News -
Sigma confirms interest in the acquisition of UK pharmacy chain Boots
June 10, 2026 - - Latest News -
Island secures US partnership to advance Galidesivir dose study for Marburg
June 10, 2026 - - Australian Biotech

